Our top pick for
CareDx Inc is a diagnostics & research business based in the US. CareDx shares (CDNA) are listed on the NASDAQ and all prices are listed in US Dollars. CareDx employs 456 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$71.00|
|52-week range||$45.96 - $99.83|
|50-day moving average||$67.86|
|200-day moving average||$76.72|
|Wall St. target price||$107.33|
|Dividend yield||$1.576 (2.22%)|
|Earnings per share (TTM)||$-0.18|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||13.38%|
|1 month (2021-09-17)||4.46%|
|3 months (2021-07-16)||-9.93%|
|6 months (2021-04-16)||-4.40%|
|1 year (2020-10-16)||37.70%|
|2 years (2019-10-16)||172.66%|
|3 years (2018-10-16)||197.82%|
|5 years (2016-10-14)||1,818.92%|
|Revenue TTM||$253.6 million|
|Gross profit TTM||$80.1 million|
|Return on assets TTM||-1.6%|
|Return on equity TTM||-2.42%|
|Market capitalisation||$3.7 billion|
TTM: trailing 12 months
There are currently 4.5 million CareDx shares held short by investors – that's known as CareDx's "short interest". This figure is 6.4% up from 4.2 million last month.
There are a few different ways that this level of interest in shorting CareDx shares can be evaluated.
CareDx's "short interest ratio" (SIR) is the quantity of CareDx shares currently shorted divided by the average quantity of CareDx shares traded daily (recently around 552159.43627451). CareDx's SIR currently stands at 8.16. In other words for every 100,000 CareDx shares traded daily on the market, roughly 8160 shares are currently held short.
However CareDx's short interest can also be evaluated against the total number of CareDx shares, or, against the total number of tradable CareDx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CareDx's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 CareDx shares in existence, roughly 90 shares are currently held short) or 0.0867% of the tradable shares (for every 100,000 tradable CareDx shares, roughly 87 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CareDx.
Find out more about how you can short CareDx stock.
We're not expecting CareDx to pay a dividend over the next 12 months.
Over the last 12 months, CareDx's shares have ranged in value from as little as $45.96 up to $99.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CareDx's is 0.6524. This would suggest that CareDx's shares are less volatile than average (for this exchange).
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.